Electronic supplementary material
The online version of this article (https://doi.org/10.1007/s12254-020-00582-4) contains supplementary material, which is available to authorized users.
All authors contributed equally to this work.
This position paper has been endorsed by the Austrian Society of Hematology and Medical Oncology (OEGHO).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Chimeric antigen receptor T cells (CAR-T cells) are a novel form of cellular immunotherapy for patients with hematologic and oncologic malignancies. Known side effects of these approved cellular immunotherapies are cytokine release syndrome, immune-cell associated neurotoxicity syndrome, cytopenias, infections and long-lasting B cell aplasia. Safe administration of CAR-T cell therapy requires thorough patient selection and patient care in qualified CAR-T cell centers.